Loading
Yanuki
KEYWORD TOPIC
President Mattarella Visits Oncology Center in Pavia, Italy | Women Form Unbreakable Bond After Meeting in Oncology Ward | Pfizer's Oncology Division Drives Growth Amidst Market Fluctuations | Merck Announces Q2 2025 Financial Results: Focus on Oncology and Animal Health | Recursion Pharmaceuticals Begins Dosing in Early-Stage B-Cell Lymphoma Study | President Mattarella Visits Oncology Center in Pavia, Italy | Women Form Unbreakable Bond After Meeting in Oncology Ward | Pfizer's Oncology Division Drives Growth Amidst Market Fluctuations | Merck Announces Q2 2025 Financial Results: Focus on Oncology and Animal Health | Recursion Pharmaceuticals Begins Dosing in Early-Stage B-Cell Lymphoma Study

News / Health

President Mattarella Visits Oncology Center in Pavia, Italy

President Sergio Mattarella's recent visit to the National Center for Oncological Hadrontherapy (CNAO) in Pavia, Italy, highlights the importance of advanced cancer treatment and research. The CNAO is one of the few facilities worldwide off...

Mattarella in visita al Cnao di Pavia: "Luogo di speranza"
President Mattarella Visits Oncology Center in Pavia, Italy Image via Sky TG24
TOPIC oncology

News / Human Interest

Women Form Unbreakable Bond After Meeting in Oncology Ward

This article highlights a touching story of friendship forged in the face of adversity, alongside news of a high-end real estate listing in Minnesota.

Women who befriended each other during cancer treatment meet annually on Lake Minnetonka to celebrate being alive

Finance / Company News

Pfizer's Oncology Division Drives Growth Amidst Market Fluctuations

Pfizer (PFE) is navigating a complex market landscape. While some analysts urge caution due to potential overvaluation after a recent 'dead cat bounce', the company's oncology division is demonstrating robust growth, driven by key drugs and...

Pfizer: Don't Be Fooled By The Dead Cat Bounce (NYSE:PFE)

Finance / Company Results

Merck Announces Q2 2025 Financial Results: Focus on Oncology and Animal Health

Merck (NYSE: MRK) released its Q2 2025 financial results, highlighting strong performance in oncology and animal health, alongside contributions from recent product launches. The company is strategically optimizing its portfolio to focus on...

Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.